search icon
  • Apple, Inc AAPL
  • S&P 500 ETF Trust SPDR SPY
  • Alphabet Inc. - Class A Shares GOOGL
  • Microsoft Corporation MSFT
  • Meta Platforms Inc META
  • Netflix, Inc. NFLX
  • Amazon.com Inc. AMZN
  • Spotify Technology SA SPOT
    nmtrq-img

    9 Meters Biopharma Inc., Common Stock

    NMTRQ

    PNK

    $0.0001

    +$0

    (0%)

    1D
    Industry: Biotechnology Sector: Health Care

    Analyst Forecast

    Overview Returns Financials Ratios News FAQs

    Price Chart

    Key Metrics

    Market Cap info-icon
    This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
     $1.45K
    P/E Ratio info-icon
    This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
     0
    Volume info-icon
    This is the total number of shares traded during the most recent trading day.
     0
    Avg Volume info-icon
    This is the average number of shares traded during the most recent 30 days.
     0
    Dividend Yield info-icon
    This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
     0.00%
    Beta info-icon
    This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
     12.89
    52-week Range info-icon
    This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
    $1 L
    $0 H
    $0.0001

    About 9 Meters Biopharma Inc., Common Stock

    9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina. more

    Industry: BiotechnologySector: Health Care

    Returns

    Time FrameNMTRQSectorS&P500
    1-Week Return-50%-1.67%1.25%
    1-Month Return--3.51%1.77%
    3-Month Return--4.17%9.07%
    6-Month Return--10.65%5.36%
    1-Year Return--12.8%19.28%
    3-Year Return-100%-2.49%48.86%
    5-Year Return-100%21.6%88.54%
    10-Year Return-100%72.94%205.26%

    Financials

    Dec '19Dec '20Dec '21Dec '22
    Total Revenue----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true}]
    Cost of Revenue----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true}]
    Gross Profit----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true}]
    Gross Margin----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true}]
    Operating Expenses24.28M21.45M31.66M42.02M[{"date":"2019-12-31","value":57.79,"profit":true},{"date":"2020-12-31","value":51.06,"profit":true},{"date":"2021-12-31","value":75.35,"profit":true},{"date":"2022-12-31","value":100,"profit":true}]
    Operating Income(24.28M)(21.45M)(31.66M)(42.02M)[{"date":"2019-12-31","value":-2428278100,"profit":false},{"date":"2020-12-31","value":-2145297800,"profit":false},{"date":"2021-12-31","value":-3165816600,"profit":false},{"date":"2022-12-31","value":-4201705100,"profit":false}]
    Total Non-Operating Income/Expense(2.77M)(40.04M)(5.12M)(1.75M)[{"date":"2019-12-31","value":-276602700,"profit":false},{"date":"2020-12-31","value":-4004351100,"profit":false},{"date":"2021-12-31","value":-512123400,"profit":false},{"date":"2022-12-31","value":-174936400,"profit":false}]
    Pre-Tax Income(27.05M)(61.50M)(36.78M)(43.77M)[{"date":"2019-12-31","value":-2704880800,"profit":false},{"date":"2020-12-31","value":-6149648900,"profit":false},{"date":"2021-12-31","value":-3677940000,"profit":false},{"date":"2022-12-31","value":-4376641500,"profit":false}]
    Income Taxes----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true}]
    Income After Taxes----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true}]
    Income From Continuous Operations(27.05M)(61.50M)(36.78M)(43.77M)[{"date":"2019-12-31","value":-2704880800,"profit":false},{"date":"2020-12-31","value":-6149648900,"profit":false},{"date":"2021-12-31","value":-3677940000,"profit":false},{"date":"2022-12-31","value":-4376641500,"profit":false}]
    Income From Discontinued Operations----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true}]
    Net Income(27.05M)(61.50M)(36.78M)(43.77M)[{"date":"2019-12-31","value":-2704880800,"profit":false},{"date":"2020-12-31","value":-6149648900,"profit":false},{"date":"2021-12-31","value":-3677940000,"profit":false},{"date":"2022-12-31","value":-4376641500,"profit":false}]
    EPS (Diluted)(0.80)(0.73)(0.15)(1.72)[{"date":"2019-12-31","value":-80,"profit":false},{"date":"2020-12-31","value":-73,"profit":false},{"date":"2021-12-31","value":-15,"profit":false},{"date":"2022-12-31","value":-172,"profit":false}]

    Ratios

    Liquidity

    These ratios help you determine the liquidity of the company. Higher is better.

    NMTRQ
    Current Ratio 0.59

    Asset Efficiency

    These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

    NMTRQ
    ROA (LTM) -111.78%
    ROE (LTM) -375.64%

    Liabilities

    These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

    NMTRQ
    Debt Ratio Lower is generally better. Negative is bad. 1.68
    Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.68

    Valuation

    These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

    NMTRQ
    Trailing PE NM
    Forward PE NM
    P/S (TTM) 0.00
    P/B 4.58
    Price/FCF NM
    EV/R 0.00
    EV/Ebitda NM

    Discover more

    Tsla

    Tesla, Inc.
    aaple

    Apple, Inc.
    GOOGL

    Alphabet Inc. - Class A Shares
    META

    Meta Platforms Inc
    AMZN

    Amazon.com Inc.
    Microsoft

    Microsoft Corporation
    NVDA

    NVIDIA Corporation
    BRK

    Berkshire Hathaway Inc. Hld B
    LLY

    Eli Lilly and Company

    FAQs

    What is 9 Meters Biopharma Inc. share price today?

    9 Meters Biopharma Inc. (NMTRQ) share price today is $0.0001

    Can Indians buy 9 Meters Biopharma Inc. shares?

    Yes, Indians can buy shares of 9 Meters Biopharma Inc. (NMTRQ) on Vested. To buy 9 Meters Biopharma Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NMTRQ stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

    Can Fractional shares of 9 Meters Biopharma Inc. be purchased?

    Yes, you can purchase fractional shares of 9 Meters Biopharma Inc. (NMTRQ) via the Vested app. You can start investing in 9 Meters Biopharma Inc. (NMTRQ) with a minimum investment of $1.

    How to invest in 9 Meters Biopharma Inc. shares from India?

    You can invest in shares of 9 Meters Biopharma Inc. (NMTRQ) via Vested in three simple steps:

    • Click on Sign Up or Invest in NMTRQ stock at the top of this page
    • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
    • Transfer USD funds to your US Brokerage account and start investing in 9 Meters Biopharma Inc. shares
    What is 9 Meters Biopharma Inc. price-to-book (P/B) ratio?

    The price-to-book (P/B) ratio of 9 Meters Biopharma Inc. (NMTRQ) is 4.58

    What is the Market Cap of 9 Meters Biopharma Inc.?

    The market capitalization of 9 Meters Biopharma Inc. (NMTRQ) is $1.45K

    What is 9 Meters Biopharma Inc.’s stock symbol?

    The stock symbol (or ticker) of 9 Meters Biopharma Inc. is NMTRQ

    Feedback

    Signup to access all features and start your US investing journey!

    • Open your account in minutes
    • Take your portfolio global, starting at just $1
    Get started

    Add ticker to compare

    Scroll to Top